📣 VC round data is live. Check it out!
- Public Comps
- Pulmonx
Pulmonx Valuation Multiples
Discover revenue and EBITDA valuation multiples for Pulmonx and similar public comparables like Pangaea Oncology, BATM Advanced Communications, Tobii, Cyclopharm and more.
Pulmonx Overview
About Pulmonx
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.
Founded
1995
HQ

Employees
291
Website
Financials (LTM)
EV
$60M
Valuation Multiples
Start free trialPulmonx Financials
Pulmonx reported last 12-month revenue of $91M and negative EBITDA of ($33M).
In the same LTM period, Pulmonx generated $68M in gross profit, ($33M) in EBITDA losses, and had net loss of ($52M).
Revenue (LTM)
Pulmonx P&L
In the most recent fiscal year, Pulmonx reported revenue of $90M and EBITDA of ($35M).
Pulmonx is unprofitable as of last fiscal year, with gross margin of 74%, EBITDA margin of (39%), and net margin of (60%).
Financial data powered by Morningstar, Inc.
Pulmonx Stock Performance
Pulmonx has current market cap of $65M, and enterprise value of $60M.
Market Cap Evolution
Pulmonx's stock price is $1.55.
Pulmonx share price increased by 21.1% in the last 30 days, and decreased by 54.4% in the last year.
Pulmonx has an EPS (earnings per share) of $-1.28.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $60M | $65M | 0.0% | 21.1% | -1.9% | -54.4% | $-1.28 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialPulmonx Valuation Multiples
Pulmonx trades at 0.7x EV/Revenue multiple, and (1.8x) EV/EBITDA.
EV / Revenue (LTM)
Pulmonx Financial Valuation Multiples
As of May 26, 2026, Pulmonx has market cap of $65M and EV of $60M.
Pulmonx has a P/E ratio of (1.3x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Pulmonx Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Pulmonx Margins & Growth Rates
Pulmonx grew revenue by 0% but EBITDA decreased by 16% in the last fiscal year.
In the most recent fiscal year, Pulmonx reported gross margin of 74%, EBITDA margin of (39%), and net margin of (60%).
Pulmonx Margins
Pulmonx Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Pulmonx Operational KPIs
Pulmonx's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.4M for the same period.
Pulmonx's Rule of 40 is (32%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Pulmonx's Rule of X is (31%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Pulmonx Competitors
Pulmonx competitors include Pangaea Oncology, BATM Advanced Communications, Tobii, Cyclopharm, Xtant Medical, Klea, Daxor, Meditera, AnteoTech and SMAIO.
Most Pulmonx public comparables operate across Medical Devices, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 4.1x | — | (62.9x) | — | |||
| 0.4x | 0.5x | 2.7x | 4.0x | |||
| 1.3x | 1.4x | 3.5x | 4.5x | |||
| 2.8x | 2.7x | (5.7x) | (5.5x) | |||
| 0.5x | 0.6x | 4.4x | 7.2x | |||
| 3.5x | — | 15.4x | — | |||
| 6.1x | 7.2x | — | — | |||
| 0.8x | — | 11.7x | — | |||
This data is available for Pro users. Sign up to see all Pulmonx competitors and their valuation data. Start Free Trial | ||||||
Pulmonx Funding History
Before going public, Pulmonx raised $161M in total equity funding, across 3 rounds.
Pulmonx Funding Rounds
Pulmonx M&A Activity
Pulmonx has acquired 1 company to date.
Last acquisition by Pulmonx was on January 8th 2015. Pulmonx acquired Aeris Therapeutics for undisclosed valuation.
Latest Acquisitions by Pulmonx
| Description | Aeris Therapeutics is a Woburn, Massachusetts-headquartered developer of bronchoscopic therapies for emphysema patients. The company advances the Aerify Absorbable Lung Sealant, delivered via catheter to seal air leaks and improve lung function. With clinical trials completed in Europe and the U.S., Aeris targets advanced COPD treatments. |
| HQ Country | |
| HQ City | Boston, MA |
| Deal Date | 8 Jan 2015 |
| Valuation | undisclosed |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all Pulmonx acquisitions and their M&A valuation multiples. Start Free Trial | |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Pulmonx
| When was Pulmonx founded? | Pulmonx was founded in 1995. |
| Where is Pulmonx headquartered? | Pulmonx is headquartered in United States. |
| How many employees does Pulmonx have? | As of today, Pulmonx has over 291 employees. |
| Who is the CEO of Pulmonx? | Pulmonx's CEO is Glendon E. French. |
| Is Pulmonx publicly listed? | Yes, Pulmonx is a public company listed on Nasdaq. |
| What is the stock symbol of Pulmonx? | Pulmonx trades under LUNG ticker. |
| When did Pulmonx go public? | Pulmonx went public in 2020. |
| Who are competitors of Pulmonx? | Pulmonx main competitors include Pangaea Oncology, BATM Advanced Communications, Tobii, Cyclopharm, Xtant Medical, Klea, Daxor, Meditera, AnteoTech, SMAIO. |
| What is the current market cap of Pulmonx? | Pulmonx's current market cap is $65M. |
| What is the current revenue of Pulmonx? | Pulmonx's last 12 months revenue is $91M. |
| What is the current revenue growth of Pulmonx? | Pulmonx revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of Pulmonx? | Current revenue multiple of Pulmonx is 0.7x. |
| Is Pulmonx profitable? | No, Pulmonx is not profitable. |
| What is the current EBITDA of Pulmonx? | Pulmonx has negative EBITDA and is not profitable. |
| What is Pulmonx's EBITDA margin? | Pulmonx's last 12 months EBITDA margin is (36%). |
| What is the current EV/EBITDA multiple of Pulmonx? | Current EBITDA multiple of Pulmonx is (1.8x). |
| What is the current FCF of Pulmonx? | Pulmonx's last 12 months FCF is ($17M). |
| What is Pulmonx's FCF margin? | Pulmonx's last 12 months FCF margin is (19%). |
| What is the current EV/FCF multiple of Pulmonx? | Current FCF multiple of Pulmonx is (3.5x). |
| How many companies Pulmonx has acquired to date? | As of May 2026, Pulmonx has acquired 1 company. |
| What was the largest acquisition by Pulmonx? | None of the M&A deals Pulmonx has completed have disclosed valuations. |
| What companies Pulmonx acquired? | Pulmonx acquired Aeris Therapeutics. |
| In how many companies Pulmonx has invested to date? | Pulmonx hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Pulmonx
Lists including Pulmonx
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.
